Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 391-406

  Liu, Yu Jing ^a   Zhang, Cheng Mei ^a   Liu, Zhao Peng ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anilinoquinazolines; Anti tumor; ATP binding; Cytotoxicity; Dual inhibitors; EGFR; EGFR inhibitors; HER2; Irreversible EGFR inhibitors; Ligands; Nonanilininoquinazolines; Reversible EGFR inhibitors; SAR

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADENOSINE TRIPHOSPHATE; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MOLECULAR SCAFFOLD; NERATINIB; PELITINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; RAF PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SAPITINIB; STEROID RECEPTOR COACTIVATOR 1; TETRAHYDROFURAN DERIVATIVE; TETRAHYDROPYRAN DERIVATIVE; THIADIAZOLE DERIVATIVE; THREONINE;

ARTICLE; BINDING SITE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL SURVIVAL; DISEASE COURSE; DNA DAMAGE; DRUG APPROVAL; DRUG SELECTIVITY; DRUG STABILITY; ELECTRON TRANSPORT; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; NONHUMAN; POINT MUTATION; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 84860524240     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800228652     Document Type: Article

References (32)

1. Choong, N.W.; Cohen, E.E.W. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit. Rev. Oncol. Hemat., 2006, 57, 25-43.
2. Yoshida, T.; Zhang, G.; Haura, E.B. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem. Pharmacol., 2010, 80, 613-623.
3. Rehder, D.S.; Chelius, D.; McAuley, A.; Dillon, T.M.; Xiao, G.; Crouse-Zeineddini, J.; Vardanyan, L.; Perico, N.; Mukku, V.; Brems, D.N.; Matsumura, M.; Bondarenko, P.V. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin 2 antibody highlights the role avidity plays in antibody activity. Biochemistry, 2008, 47, 2518-2530.
4. Chen, H.X.; Cleck, J.N.; Coelho, R.; Dancey, J.E. Epidermal growth facotr receptor inhibitors: current status and future directions. Curr. Probl. Cancer, 2009, 33, 245-294.
5. Sebastian, S.; Settleman, J.; Reshkin, S.J.; Azzariti, A.; Bellizzi, A.; Paradiso, A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta, 2006, 1766, 120-139.
6. Bianco, R.; Gelardi, T.; Damiano, V.; Ciardiello, F.; Tortora, G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int. J. Biochem. Cell Biol., 2007, 39, 1416-1431.
7. Chan, S.K.; Gullick, W.J.; Hill, M.E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur. J. Cancer, 2006, 42, 17-23.
8. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.-H.; Li, D.; Capelletti, M.; Cortot, A.B.; Chirieac, L.; Iacob, R.E.; Padera, R.; Engen, J.R.; Wong, K.-K.; Eck, M.J.; Gray, N.S.; Jänne, P.A. Novel mutantselective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462, 1070-1074.
9. Cardó-Vila, M.; Giordano, R.J.; Sidman, R.L.; Bronk, L.F.; Fan, Z.; Mendelsohn, J.; Arap, W.; Pasqualini, R. From combinatorial peptide selection to drug prototype (): targeting the epidermal growth factor receptor pathway. Proc. Natl. Acad. Sci. USA, 2010, 107, 5118-5123.
10. Ballard, P.; Bradbury, R.H.; Hennequin, L.F.A.; Hickinson, D.M.; Johnson, P.D.; Kettle, J.G.; Klinowska, T.; Morgentin, R.; Ogilvie, D.J.; Olivier, A. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorg. Med. Chem. Lett., 2005, 15, 4226-4229.
11. Ballard, P.; Bradbury, R.H.; Harris, C.S.; Hennequin, L.F.A.; Hickinson, M.; Johnson, P.D.; Kettle, J.G.; Klinowska, T.; Leach, A.G.; Morgentin, R.; Pass, M.; Ogilvie, D.J.; Olivier, A.; Warin, N.; Williams, E.J. Inhibitors of epidermal growth factor receptor tyrosine kinase: novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorg. Med. Chem. Lett., 2006, 16, 1633-1637.
12. Domarkas, J.; Dudouit, F.; Williams, C.; Qiu, Q.; Banerjee, R.; Brahimi, F.; Jean-Claude, B.J. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J. Med. Chem., 2006, 49, 3544-3552.
13. Rachid, Z.; Brahimi, F.; Qiu, Q.; Williams, C.; Hartley, J.M.; Hartley, J.A.; Jean-Claude, B.J. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexpressing solid tumors: discovery of an unusual structure-activity relationship. J. Med. Chem., 2007, 50, 2605-2608.
14. Rachid, Z.; MacPhee, M.; Williams, C.; Todorova, M.; Jean-Claude, B.J. Design and synthesis of new stabilized combitriazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorg. Med. Chem. Lett., 2009, 19, 5505-5509.
15. Liu, L.T.; Yuan, T.-T.; Liu, H.-H.; Chen, S.-F.; Wu, Y.-T. Synthesis and biological evaluation of substituted 6-alkynyl-4- anilinoquinazoline derivatives as potent EGFR inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 6373-6377.
16. Michalczyk, A.; Klüter, S.; Rode, H.B.; Simard, J.R.; Grütter, C.; Rabiller, M.; Rauh, D. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg. Med. Chem., 2008, 16, 3482-3488.
17. Carmi, C.; Cavazzoni, A.; Vezzosi, S.; Bordi, F.; Vacondio, F.; Silva, C.; Rivara, S.; Lodola, A.; Alfieri, R.R.; Monica, S.L.; Galetti, M.; Ardizzoni, A.; Petronini, P.G.; Mor, M. Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. J. Med. Chem., 2010, 53, 2038-2050.
18. Ban, H.S.; Usui, T.; Nabeyama, W.; Morita, H.; Fukuzawa, K.; Nakamura, H. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. Org. Biomol. Chem., 2009, 7, 4415-4427.
19. Nakamura, H.; Horikoshi, R.; Usui, T.; Ban, H.S. Selective inhibition of EGFR and VEGFR2 tyrosine kinases controlled by a boronic acid substituent on 4-anilinoquinazolines. Med. Chem. Commun., 2010, 1, 282-286.
20. VanBrocklin, H.F.; Lim, J.K.; Coffing, S.L.; Hom, D.L.; Negash, K.; Ono, M.Y.; Gilmore, J.L.; Bryant, I.; Riese, D.J. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J. Med. Chem., 2005, 48, 7445-7456.
21. Hennequin, L.F.A.; Ballard, P.; Boyle, F.T.; Delouvrié, B.; Ellston, R.P.A.; Halsall, C.T.; Harris, C.S.; Hudson, K.; Kendrew, J.; Pease, J.E.; Ross, H.S.; Smith, P.; Vincent, J.L. Novel 4- anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 2672-2676.
22. Ban, H.S.; Onagi, S.; Uno, M.; Nabeyama, W.; Nakamura, H. Allene as an alternative functional group for drug design: effect of C-C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase. ChemMedChem, 2008, 3, 1094-1103.
23. Ban, H.S.; Tanaka, Y.; Nabeyama, W.; Hatori, M.; Nakamura, H. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines. Bioorg. Med. Chem., 2010, 18, 870-879.
24. Chandregowda, V.; Kush, A.K.; Chandrasekara Reddy, G. Synthesis and in vitro antitumor activities of novel 4- anilinoquinazoline derivatives. Eur. J. Med. Chem., 2009, 44, 3046-3055.
25. Wu, X.; Li, M.; Qu, Y.; Tang, W.; Zheng, Y.; Lian, J.; Ji, M.; Xu, L. Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorg. Med. Chem., 2010, 18, 3812-3822.
26. Abouzid, K.; Shouman, S. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. Bioorg. Med. Chem., 2008, 16, 7543-7551.
27. Cha, M.Y.; Lee, K.-O.; Kim, J.W.; Lee, C.G.; Song, J.Y.; Kim, Y.H.; Lee, G.S.; Park, S.B.; Kim, M.S. Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her- 1 selective inhibitor-resistant non-small cell lung cancer. J. Med. Chem., 2009, 52, 6880-6888.
28. Chilin, A.; Conconi, M.T.; Marzaro, G.; Guiotto, A.; Urbani, L.; Tonus, F.; Parnigotto, P. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold. J. Med. Chem., 2010, 53, 1862-1866.
29. Ballard, P.; Bradbury, R.H.; Harris, C.S.; Hennequin, L.F.A.; Hickinson, M.; Kettle, J.G.; Kendrew, J.; Klinowska, T.; Ogilvie, D.J.; Pearson, S.E.; Williams, E.J.; Wilson, I. Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics. Bioorg. Med. Chem. Lett., 2006, 16, 4908-4912.
30. Kitano, Y.; Suzuki, T.; Kawahara, E.; Yamazaki, T. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 5863-5867.
31. Lüth, A.; Löwe, W. Syntheses of 4-(indole-3-yl)quinazolines - a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur. J. Med. Chem., 2008, 43, 1478-1488.
32. Wissner, A.; Fraser, H.L.; Ingalls, C.L.; Dushin, R.G.; Floyd, M.B.; Cheung, K.; Nittoli, T.; Ravi, M.R.; Tan, X.; Loganzo, F. Dual irreversible kinase inhibitiors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFE-2. Bioorg. Med. Chem., 2007, 15, 3635-3648.